Principal Financial Group
OREX

Principal Financial Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Principal Financial Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,731
Closed -$10K – 2273
2016
Q1 		$10K Sell
1,731
-89,450
-98% -$1.16M ﹤0.01% 2168
2015
Q4 		$1.57M Hold
91,181
– – ﹤0.01% 1692
2015
Q3 		$1.92M Buy
91,181
+37,959
+71% +$1.3M ﹤0.01% 1655
2015
Q2 		$2.63M Buy
53,222
+5,155
+11% +$308K ﹤0.01% 1624
2015
Q1 		$3.76M Sell
48,067
-271
-0.6% -$16.8K 0.01% 1488
2014
Q4 		$2.93M Sell
48,338
-3,529
-7% -$177K ﹤0.01% 1595
2014
Q3 		$2.21M Buy
51,867
+1,784
+4% +$95.8K ﹤0.01% 1634
2014
Q2 		$3.1M Sell
50,083
-667
-1% -$38.8K 0.01% 1596
2014
Q1 		$3.3M Buy
50,750
+1,960
+4% +$133K 0.01% 1547
2013
Q4 		$2.75M Buy
48,790
+790
+2% +$44.4K 0.01% 1608
2013
Q3 		$2.95M Sell
48,000
-3,145
-6% -$213K 0.01% 1531
2013
Q2 		$2.99M Buy
+51,145
New +$3.15M 0.01% 1469

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Principal Financial Group's OREX Position: Q2 2016 in Review

Principal Financial Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 1,731 shares — an estimated $10K sold.

Principal Financial Group first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $3.76M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Principal Financial Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Principal Financial Group sold 1,731 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $10K.
  • Principal Financial Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Principal Financial Group's Orexigen Therapeutics, Inc. position peaked at $3.76M in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Principal Financial Group's 13F filing for Q2 2016, filed 9 Aug 2016.